secwatch.observer — SEC 8-K summary
======================================

Issuer:     Scholar Rock Holding Corp (SRRK)
CIK:        0001727196
Form:       8-K
Filed at:   2024-03-19T23:59:59+00:00
Accession:  0001104659-24-035865
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Scholar Rock reports FY2023 net loss of $165.8M; cash $280M; SAPPHIRE data expected 4Q 2024
--------------------------------------------------------------------------------

- Net loss $165.8M ($1.99/share) vs $134.5M ($2.26/share) in FY2022; no revenue vs $33.2M prior year.
- R&D spend $121.9M, G&A $49.4M; cash $280M expected to fund operations into 2H 2025.
- Phase 3 SAPPHIRE trial (apitegromab in SMA) topline data on track for 4Q 2024; potential launch 2025 if approved.
- FDA cleared IND for Phase 2 obesity trial of apitegromab + GLP-1 RA; start mid-2024, data mid-2025.
- Appointed Katie Peng to board; promoted Mo Qatanani to CSO in Feb 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1727196/000110465924035865/0001104659-24-035865-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1727196/000110465924035865/tm249126d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-035865

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer